Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
eNq1mF1v2jAUhu/5FVEudkcCLVDYEqqNwYbUaoyCNu0GmeRQzIKd+oOP/fo5BFSYHLEafJk4ec+xz/HjVw7uN8vEWQHjmJLQrXoV1wES0RiT59Adj3rlpnvfLgULtEJHn915Fa964zpRgjgP3WzUmwIi3Pv5+PAZ1P/A3HbJCeh0AZE4+U4KnHhfEZ8/ojT7xglWFMfOEsScxqGbSrF76wRcMJVFe03Zb56iCAJ//+Z4dDGpHb8P/EzsP1QlB/aAyLNWFIiRZiQZAyI6SMAzZduCfG+NtDEfAqeSRTBAYj5gdIVjiLUhZijhYBRkto6fgK0SEFkQrbi/iJbcSBwt0GYIL3190h/VaEdsRLlSrt41aq3bWq3eqtabRqHY0VLpq6Am4UeTZqNx17rxgfgoUl25NVw2zAeUCZRYqgrmndPGshSHwcvZ6seYpwnaeguemi4VYkgNA1Pb395EshmMmAJSotbsH30ik8R/Y9bjPS4sZZzRqEMlEQXU6A1NF6JDiYBNcUXNQCc2+17EwK8n+4cSPeQHcprgyBRpCjoSuBgP+8VEuyYMPiEOY2aPBj8wiemaX58yx1W1lH26A6VWNGVxdXLTajaq9brxJvqlWqjghOlKRlPwFX8wvwQrfTKjlwJFdaVe6tCTV2vHnc+hEUqgwOmUDdmi+vBgzKx1ur1dlA9oRb90R6bt8V0C2z7tHrXSOA4PhTXjrg2Yq148l3e+a8N0clupN5U1e4eW6YeDgw4N3XIuasUsS6ZHzFyIlL/3/fV67c0RL3Ok1tObseIj4F479WtMX/H2tZr2/LyV8z/3QzlrLaU+zQ/Rt5XRdN+ecwiXut79/3t3rY0hmIQLapEj3hqI+93rs/3V8lpLe3CCGHthdvYUCUyJLdskp1rFi04TVVbSY4oP32YzXHC9UtiWgZ9f7bRLgZ9d67RLfwHGPwFE
2m4RLMX30pqFFywC
Listen
